We retrospectively evaluated the incidence, risk factors for chronic graft-versus-host disease (cGvHD) and outcome in 80 pediatric patients (36 male) (median age 13 years) who underwent allogeneic peripheral blood progenitor cell transplantation. Patients were grafted from an HLAidentical sibling after myeloablative conditioning (total body irradiation (TBI) based 52; non-TBI 28). GvHD prophylaxis used were: cyclosporin A (CsA) þ short methotrexate (MTX) in 52 and CsA7prednisone in 28. The median number of CD34 þ cells infused were 5.8 Â 10 6 /kg (range: 1.4-32.8). The median follow-up was 24 months (range: 3-94). In all, 28 patients had cGvHD (confidence interval (CI): 54.2710%). Factors that were significant on univariate analysis were diagnosis (P ¼ 0.03) and GvHD prophylaxis administered (P ¼ 0.04). On multivariate analysis, only GvHD prophylaxis used was associated with a significant risk of cGvHD (hazard ratio (HR): 3.94; 95% CI: 1.41-10.91, P ¼ 0.009). The CI of cGvHD for patients receiving CsA þ MTX was 40.9712 vs 76.5718% for patients who did not (P ¼ 0.03). The probability of relapse was 3676% for all patients (12.578% for patients with cGvHD vs 47.978% without cGvHD). The probability of disease-free survival was better for patients with cGvHD (69.9710 vs 37.977%; HR: 3.59, 95% CI: 1.47-5.56; P ¼ 0.001). Our data suggest that the GvHD prophylaxis used is the most relevant predictor of cGvHD. Patients with cGvHD had a lower risk of relapse and a better survival.
pheral blood transplantation
Chronic graft-versus-host disease (cGvHD) is one of the most important causes of morbidity and mortality following allogeneic stem cell transplantation. In fact, cGvHD is the leading cause of nonrelapse mortality beyond 2 years after allogeneic transplantation. 1 The incidence of cGvHD is increasing during the last years probably due to changes in clinical stem cell transplantation practice. 2 These changes are mainly related to the increased use of matched unrelated donors, donor lymphocyte infusion to prevent or treat leukemia relapse and mobilized peripheral blood progenitor cells (PBPC) instead of bone marrow as the source of hematopoietic stem cells.
Cytokine-mobilized PBPC for allogeneic transplantation has been mainly used in adults. Its use has been associated with faster hematological 3 and immunological 4 recovery, shorter hospitalization, 5 lesser regimen-related toxicity 6 and lower initial costs 7 compared to the use of bone marrow, but it seems to be associated with an increased incidence of cGvHD. 8 However, this source of hematopoietic stem cell has been less extensively used for allogeneic transplantation in children, in part due to concerns with regard to pediatric donor safety. 9, 10 Thus, there are few reported experiences, especially focused on cGvHD, 11 in children receiving allo-PBPC. To gain more information with regard to this controversial issue, we evaluated the incidence, risk factors and outcome of cGvHD in a pediatric patient series with hematological malignancies receiving an allogeneic PBPC transplantation from an HLA-identical sibling donor.
Patients, donors and methods

Patient selection
A total of 80 pediatric patients from eight Spanish Institutions, who received granulocyte colony-stimulating factor (G-CSF) mobilized PBPC transplantation from an HLA-identical sibling donor as a first transplant for hematological malignancies between January 1995 and January 2003 were included in this study. All patients received a myeloablative preparatory regimen and an unmanipulated blood stem cell graft. Details of blood stem cell mobilization and collection have been described previously. 12 Informed consent was obtained for all procedures from each subject or subject's parents or guardians. Patients, donors and transplantation characteristics are shown in Table 1 .
Study definitions and outcomes
The clinical outcomes analyzed were time to neutrophil and platelet recovery, the onset of aGvHD (grade II-IV) and cGvHD, time to transplant-related mortality (TRM), time to disease relapse and disease-free survival (DFS). Time to neutrophil engraftment was defined as the first of 3 consecutive days in which the absolute neutrophil count exceeded 0.5 Â 10 9 /l. Time to platelet recovery was defined as the first of 3 consecutive days in which the absolute platelet count exceeded 20 Â 10 9 /l without platelet transfusion during a seven days period. The diagnosis of acute and chronic GvHD was based on clinical standard criteria with histologic confirmation whenever possible. 13, 14 Disease status at transplantation was considered early for patients in first remission or first chronic phase, intermediate for patients in second remission, second chronic phase or accelerate phase, and advanced for those in later remission, blast crisis or transplanted in relapse.
Statistical methods
At the time of analysis (August 2003), the minimum followup was 3 months after transplantation. The actuarial curves of relapse incidence (RI) and DFS were obtained using the Kaplan-Meier method 15 and the differences between groups were compared using log-rank test. Estimates of cumulative incidence of cGvHD were used in considering death or relapse without cGvHD as a competing risk. Proportional-hazard regression model was used for univariate and multivariate analyses of risk factors for cGvHD. 16 The variables considered in this analysis were: patient age and gender, female donor for male patient, cytomegalovirus (CMV) serostatus for each recipient and donor pair, disease type (AML, ALL, CML), disease status at transplantation, conditioning regimen used (total body irradiation (TBI) based vs chemotherapy based), GvHD prophylaxis (short methotrexate (MTX) þ cyclosporin A (CsA) vs others), grades II-IV aGvHD (no vs yes), number of CD34 þ and CD3 þ cells infused and the postinfusion use of G-CSF (yes vs no). Variables that were found significant in univariate analysis were included in multivariate analysis. The P-value threshold for multivariate analysis was 0.2. All data were computed and analyzed using SPSS software (SPSS, Inc., Chicago, IL, USA).
Results
Incidence and risk factors for cGvHD
Out of 80 patients, 28 (35%) had cGvHD. In 20 of them (72%), cGvHD was clinically extensive. The cumulative incidence of cGvHD at 24 months was 54.2710%. The cumulative incidence of aGvHD grade II-IV at 24 months was 3775%. Factors that were found significant in univariate analysis were: diagnosis (P ¼ 0.03) and GvHD prophylaxis regimen used (P ¼ 0.04). A trend to higher risk of cGvHD was found with the number of CD34 þ and CD3 þ cells infused when analyzed dichotomously above or below the median (Table 2) . No significant increased risk of cGvHD was found with patient sex and age, disease status at transplantation, preparatory regimen used, CMV serology prior to transplantation, aGvHD grade II-IV or using postinfusion G-CSF (Table 2) . Only the GvHD prophylaxis regimen used (other than CsA þ short MTX) was associated with a significant increase of risk of cGvHD (hazard ratio (HR): 3.94; 95% confidence interval (CI): 1.41-10.91, P ¼ 0.009) in multivariate analysis. The (Figure 1 ).
Influence of cGvHD on RI, TRM and DFS
The probability of relapse was 3676% for all patients, 12.578% for patients with cGvHD and 47.978% for patients without cGvHD (Figure 2 ). There was a trend towards increased TRM in patients with cGvHD (3077 vs 1476%; P ¼ 0.1). The probability of DFS was higher for patients with cGvHD (69.9710 vs 37.977%; HR: 3.59, 95% CI: 1.47-5.56; P ¼ 0.001) (Figure 3) . 
Discussion
This retrospective and multicenter study was conducted for evaluating the incidence, risk factors for cGvHD and the effect of cGvHD on clinical outcome in terms of TRM, RI and DFS. Data of pediatric patients undergoing an allogeneic PBPC transplantation and reported to the Spanish Group of Allogeneic-PBT were included. All patients were transplanted for hematological malignancies and received an unmanipulated PBPC graft from an HLAidentical sibling donor after a myeloablative regimen. The main findings of the present study are that the usually considered risk factors for cGvHD in bone marrow were not found associated with an increased risk of cGvHD, and patients with cGvHD had a lower risk of relapse and a better DFS. Allogeneic PBPC transplantation is increasingly used in the treatment of malignancies in adults. 2 However, in children there is scarce experience 9, 11 in part due to unresolved medical and ethical concerns with regard to short-and long-term effects of G-CSF on healthy pediatric donors 10, 12 and the possible increased risk of cGvHD when using mobilized PBPC instead BM for allogeneic transplantation. 11 This issue is still controversial since many studies in adults did not find an increased risk of cGvHD, 3, 17 whereas other studies did. 18, 19 However, there are no reported prospective randomized studies in children, comparing incidence of cGvHD between BM or PBPC in allogeneic transplantation. The reported incidence in this study is clearly higher than previously reported in children using allogeneic bone marrow transplantation. Kondo et al 20 found an incidence of cGvHD of 22%, quite similar to previously reported by others. [21] [22] [23] [24] A matched-pair study in pediatric patients showed an increased incidence of cGvHD in the PBPC group compared to the BM group, although the difference was not statistically significant. 11 However, Levine et al 25 found a probability of cGvHD of 75% at 1 year, very similar to what we have found in patients who did not receive MTX as GvHD prophylaxis.
In the few published studies focused on risk factors for cGvHD in children, [20] [21] [22] [23] [24] all of them using bone marrow as hematopoietic stem cell source, recipient older age, female donor to male recipient, diagnosis of malignancy and the use of TBI as preparative regimen were found significantly related to an increased risk of cGvHD in multivariate analysis. However, there are no previously published studies with regard to this issue in children using PBPC as the hematopoietic stem cell source. In our study, none of the above-mentioned risk factors were found associated to an increased risk of cGvHD.
Recipient age was not found to be a risk factor, but the median age of patients in this series is higher than reported by others. This might explain the high incidence of cGvHD in the present study.
Malignancy compared to nonmalignant disease has been found as a risk factor for cGvHD. Carlens et al 26 reported an increased risk of cGvHD in patients transplanted for CML. In our study, acute leukemia and CML patients had a lower risk of cGvHD than lymphoma patients. This may be due to the small population of lymphoma patients. Diagnosis lost significance in the multivariate analysis.
Sex mismatch, especially female donor to male recipient, has been recognized as a risk factor for cGvHD based on alloimmunization by previous pregnancies. We did not find this association probably due to the fact that the majority of female donors were not previously alloimmunizated. However, some authors have suggested that a primary immune response towards male antigens may produce cGvHD. 22 Prior aGvHD has been recognized as one of the most important risk factors for cGvHD. 27 However, this post transplant event is influenced by many other pretransplant characteristics such as CMV serostatus, sex mismatch, older age and mainly the prophylaxis regimen used. GvHD prophylaxis other than MTX-containing regimen has been associated with a higher risk of acute and cGvHD after marrow transplantation. 28 Moreover, attenuation in MTX dosage or suppression of day 11 MTX dose have also been associated with higher risk of cGvHD. 29 In a randomized study comparing allogeneic blood and bone marrow transplantation, Powles et al 17 found no difference in the cGvHD incidences between both groups. They pointed out that it could be due to the use of MTX at full doses in the prophylaxis GvHD regimen. Patients receiving PBPC allografts may need more immunosuppression. Our data would be in accordance with this.
More recently, the number of CD34 þ cells and CD3 þ cells in the graft have been considered of relevance in the outcome of allogeneic PBPC transplantation. [30] [31] [32] In our study, a trend towards high incidence of cGvHD was observed with a dose of donor CD3 þ above median. However, no conclusions have been obtained with regard to this issue in several randomized studies due to the limited number of cGvHD observations. 8 It has also been published that high CD34 þ cell doses correlated with aGvHD, 30 and some authors have recently found a detrimental effect on transplantation outcome when high doses of CD34 þ cells are infused, mainly due to an increased late mortality from cGvHD. 31 However, a large retrospective study published recently failed to find a relationship between high doses of CD34 þ cells and aGvHD, while some evidence was found that cGvHD was more frequent with high doses of CD34 þ cells. 33 We have only found a trend towards a higher cGvHD incidence in patients who received higher doses of CD34 þ cells. This may be due to the limited number of patients in the present study who may not have been sufficient for detection of a difference that might truly exist.
cGvHD is the major cause of late mortality in patients surviving beyond 2 years after transplantation. 1 However, the clinical consequences of cGvHD are not always negative. cGvHD is associated with lower leukemia relapse after bone marrow transplantation. 34 This graft-versusleukemia effect (GvL) was more clear in patients transplanted in the advanced stage of the disease. 35 Recently, Brunet et al 36 have reported a clinical benefit in terms of reduction of leukemia relapse in patients with advanced hematological diseases grafted with unmanipulated PBPC. The GvL effect is poorly understood but at least two different mechanisms have been proposed to explain the hypothetically stronger GvL effect associated with PBPC transplantation. One is related with the high number of donor CD3 þ cells in the graft. High amounts of donor CD3 þ cells may provide a more prominent and protracted GvL reaction. 37 The other one is related with the high number of hematopoietic progenitors infused resulting in a more rapid expansion of normal hematopoiesis. 38 Our data clearly show that the presence of cGvHD resulted on a lower RI with no significant difference in nonrelapse mortality. This resulted on a better DFS.
In conclusion, our data suggest that the incidence of cGvHD after allogeneic PBPC transplantation in children seems to be higher than reported while using bone marrow. The GvHD prophylaxis regimen used was the most relevant predictor of cGvHD. Patients with cGvHD had a lower risk of relapse and a better DFS. We are aware that these observations are based on a retrospective study and, therefore, conclusions should be taken with caution and validated in a prospective study.
